Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801334 | 0.94 | CA14 (0.40) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL3193199 | 0.84 | MEN1 (0.40) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL2324579 | 0.84 | MEN1 (0.40) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL3670762 | 0.83 | CYP2D6 (0.41) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL4095492 | 0.82 | CA14 (0.46) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL7431200 | 0.82 | CA14 (0.46) | CA14CA12CA2CA1CYP2D6 | |
| SCHEMBL29023037 | 0.79 | GAA (0.45) | CA14TSHRGAAKMT2A | |
| SCHEMBL13613755 | 0.79 | CA12 (0.44) | CA14CA12CA2CA1CA7 | |
| SCHEMBL2153082 | 0.78 | CA12 (0.50) | CA14CA12CA2CA1CA7 | |
| SCHEMBL14206399 | 0.78 | CA12 (0.50) | CA14CA12CA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674803-B2 | Thiazolypiperidine derivatives as MTP inhibitors | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-1636218-B1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MERCK PATNET GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MTTP, CETP, APOB | CA14 4880/4885CA12 4863/4885CA2 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.